跳至主要内容
临床试验/EUCTR2008-005167-33-DE
EUCTR2008-005167-33-DE进行中(未招募)1 期

Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease - GABATAX

Charité University Medicine Berlin0 个研究点开始时间: 2010年3月16日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • patient written informed consent
  • age 18 - 75 years
  • diagnosed with multiple sclerosis or hereditary spinocerebellar ataxia or late onset idiopathic cerebellar ataxia
  • ataxia since at least 3 months (multiple sclerosis) or 1 year (hereditary spinocerebellar ataxia and idiopathic late onset ataxia)
  • highly effective contraception for women (defined as Pearl index < 1)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • pregnancy or lactation
  • all contraindications against gabapentin
  • medication with morphine, naproxen or pregabalin, interferon
  • medication with gabapentin in past 3 months
  • no consent for Speicherung und Weitergabe of pseudonymised clinical data
  • forced hospitalization
  • Alcohol abuse in last 10 years
  • Allergy against gabapentin or another ingredient of trial medication
  • acute oder chronic pancreatitis
  • kidney insufficience
  • liver insufficience
  • no ability to walk even with assistance
  • fast disease progression (worsening in neurologic examination in last 2 months)
  • participation in another treatment trial up to 2 months before and during the GABATAX trial

研究者

相似试验